Hong Kong Chemicals Stock News

Chinese biotech company Hansoh Pharmaceutical Group has entered a licensing agreement worth up to US$1.45 billion with Roche, granting Roche exclusive global rights to develop, manufacture, and commercialise an investigational treatment for colorectal cancer and other solid tumours. This collaboration gives Hansoh access to a major global pharmaceutical partner and spotlights the company's advancing drug pipeline in oncology. We’ll examine what this expansive partnership with Roche could...

On October 17, 2025, Precision Tsugami (China) announced that it expects to report a profit attributable to owners of approximately RMB 502 million for the half-year ended September 30, 2025, representing a substantial increase compared to the prior-year period. The anticipated improvement reflects rising demand in sectors such as new energy vehicles and artificial intelligence, as well as operational efficiencies boosting profitability. We'll explore how strengthening demand from emerging...

As global markets navigate a landscape marked by U.S.-China trade tensions and monetary policy shifts, investors are increasingly looking toward Asia for opportunities in dividend stocks. In such a dynamic environment, a good dividend stock is typically characterized by its ability to maintain stable payouts and demonstrate resilience amid economic fluctuations.

Key Insights AInnovation Technology Group's significant retail investors ownership suggests that the key decisions are...

Chia Tai Enterprises International's (HKG:3839) stock is up by a considerable 50% over the past three months. Given...

We think all investors should try to buy and hold high quality multi-year winners. While the best companies are hard to...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

As global markets navigate a period of volatility marked by trade tensions and monetary policy shifts, investors are increasingly turning their attention to Asia for opportunities. In this context, dividend stocks can offer a compelling option for those seeking income stability amid economic uncertainties.

As the Asian tech sector navigates a landscape marked by evolving U.S.-China trade dynamics and ongoing economic adjustments, investors are keenly observing how these factors impact growth trajectories. In such an environment, identifying high-growth tech stocks involves assessing companies that demonstrate resilience through innovation and adaptability in response to shifting market conditions.

As global markets navigate a landscape of economic uncertainties, including U.S.-China trade tensions and monetary policy shifts, Asian equities present intriguing opportunities for value investors. In this environment, identifying undervalued stocks becomes crucial as investors seek companies with strong fundamentals that are trading below their intrinsic value estimates.

If you have been watching Sino Biopharmaceutical, you are probably wondering what to make of this stock after such a rollercoaster ride. The past year has brought a surge that few predicted, with the stock up an eye-catching 135.6% since the start of the year and 95.3% over the last twelve months. Even looking back three years, the company has notched an impressive 83.5% gain. Yet, this momentum hit a speed bump recently, with prices dropping 6.7% in the last week and falling 13.2% over the...

Meitu (SEHK:1357) shares have seen a dip, with the stock slipping over 5% in recent trading. Investors are watching closely as the company navigates shifting market sentiment and re-evaluates its business strategies. See our latest analysis for Meitu. Meitu's recent slide comes after a year marked by dramatic momentum shifts, with the share price posting an impressive year-to-date return of 185.76%. Short-term volatility aside, long-term investors have enjoyed a stellar one-year total...

Simcere Pharmaceutical Group (SEHK:2096) has advanced its oncology program with the first U.S. patient dosed in the Phase 1 trial of SIM0505 for advanced solid tumors. This development expands the clinical reach beyond China and draws investor attention to ongoing trial progress. See our latest analysis for Simcere Pharmaceutical Group. Simcere’s recent momentum is hard to miss, with the stock’s 91.5% year-to-date share price return fueled by progress in its expanding oncology pipeline...

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...

MMG Limited ( HKG:1208 ) shareholders might be concerned after seeing the share price drop 10% in the last week. But in...

With its stock down 13% over the past week, it is easy to disregard Kuaishou Technology (HKG:1024). But if you pay...

Affluent Foundation Holdings Limited's ( HKG:1757 ) price-to-sales (or "P/S") ratio of 2.1x may not look like an...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Most readers would already be aware that LifeTech Scientific's (HKG:1302) stock increased significantly by 12% over the...

SITC International Holdings' (HKG:1308) stock is up by a considerable 18% over the past three months. Since the market...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Key Insights Significant control over China XLX Fertiliser by individual investors implies that the general public has...

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...